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Abstract
Functional outcomes at 12 months were a secondary outcome of the randomized DECRA trial of early decompressive
craniectomy for severe diffuse traumatic brain injury (TBI) and refractory intracranial hypertension.
In the DECRA trial, patients were randomly allocated 1:1 to either early decompressive craniectomy or intensive medical
therapies (standard care). We conducted planned secondary analyses of the DECRA trial outcomes at 6 and 12 months,
including all 155 patients.
We measured functional outcome using the Glasgow Outcome Scale-Extended (GOS-E). We used ordered logistic regression, and
dichotomized the GOS-E using logistic regression, to assess outcomes in patients overall and in survivors. We adjusted analyses for
injury severity using the International Mission for Prognosis and Analysis of Clinical Trials in TBI (IMPACT) model.
At 12 months, the odds ratio (OR) for worse functional outcomes in the craniectomy group (OR 1.68; 95% confidence
interval [CI]: 0.96-2.93; p = 0.07) was no longer significant. Unfavorable functional outcomes after craniectomy were 11%
higher (59% compared with 48%), but were not significantly different from standard care (OR 1.58; 95% CI: 0.84-2.99;
p = 0.16). Among survivors after craniectomy, there were fewer good (OR 0.33; 95% CI: 0.12-0.91; p = 0.03) and more
vegetative (OR 5.12; 95% CI: 1.04-25.2; p = 0.04) outcomes.
Similar outcomes in survivors were found at 6 months after injury. Vegetative (OR 5.85; 95% CI: 1.21-28.30; p = 0.03)
and severely disabled outcomes (OR 2.49; 95% CI: 1.21-5.11; p = 0.01) were increased.
Twelve months after severe diffuse TBI and early refractory intracranial hypertension, decompressive craniectomy did not
improve outcomes and increased vegetative survivors.
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Introduction
Traumatic brain injury (TBI) imposes a heavy global burdenon health care systems,1 which is largely due to the 60% of
patients with severe TBI who die or are severely disabled and
permanently dependent.2–5 Therapies aim to reduce disability, in
addition to saving lives.
In intensive care units (ICUs) therapeutic protocols for TBI aim to
control intracranial pressure (ICP) below accepted thresholds to
minimize secondary brain injury. Guidelines recommend early
therapies to lower ICP including optimized sedation, analgesia, os-
motherapy, and cerebrospinal fluid drainage via external ventricular
drainage catheters.6–8 Brain tissue oxygen monitoring may also as-
sist choice and titration of therapies.9 In some patients, however,
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increased ICP is refractory to these therapies, and therapeutic options
then include barbiturate infusions, decompressive craniectomy sur-
gery, or therapeutic hypothermia.7,8,10 Each option has the potential
for adverse side effects, and there is controversy regarding each.
Functional outcomes after TBI may improve at least up to 12
months after TBI. Further, benefits from neurosurgery may take 12
months to become apparent,11 and complications from neurosur-
gery may take 12 months to improve. Twelve months may therefore
be an optimal time to report long-term patient outcomes in ran-
domized trials of neurosurgical interventions for patients with TBI.
The randomized early DECompressive CRAniectomy (DECRA)
trial12 included 155 adults under the age of 60 years with diffuse TBI
and intracranial hypertension refractory to usual therapies (excluding
hypothermia and barbiturates), during the first 72 h after admission.
Patients with mass lesions were excluded. Patients required persis-
tent unstimulated ICP elevation above the threshold of 20 mm Hg13
after optimized sedation, normalization of arterial carbon dioxide
pressure, and the use of mannitol, hypertonic saline, neuromuscular
blockade, and external ventricular drainage, but before hypothermia
or thiopentone infusions. Patients in both groups could receive bolus
thiopentone pre-randomization, and this usually occurred during
computed tomography (CT) scanning or consent procedures. DE-
CRA compared early bi-fronto-temporo-parietal decompressive
craniectomy surgery in addition to usual intensive medical care,
which usually included high-dose barbiturate infusions. At 6 months,
functional outcomes after craniectomy were worse.12 Functional
outcomes at 12 months, both overall and in survivors, were planned
secondary outcomes14 of this randomized trial.
The RESCUEicp trial11 enrolled 408 patients with severe TBI,
cerebral mass lesions, or diffuse brain injury considerably later after
injury, and at a higher ICP threshold (25 mm Hg). In RESCUEicp,
either bi-fronto-temporal or unilateral craniectomy was permitted,
whereas in DECRA all patients with craniectomy had diffuse injury
and received a bi-fronto-temporo-parietal procedure. In RES-
CUEicp, patients had intracranial hypertension refractory to usual
therapies (including hypothermia) up to 10 days after admission,
whereas in DECRA patients were randomized during their first 72 h.
Both trials permitted late decompressive craniectomy in the control
group as a life-saving measure and this ‘‘crossover’’ occurred in
37.2% of standard care patients in RESCUEicp, compared with 18%
in DECRA. In RESCUEicp, at 6 months mortality was lower after
craniectomy (26.9%) than in standard care patients, who had a high
mortality rate (48.5% compared with 19% in DECRA).12 At 12
months, the proportion of patients in RESCUEicp with at least partial
independence (Glasgow Outcome Scale-Extended [GOS-E] score of
4 or better, and termed favorable outcome in this trial) was greater
than in controls, but the proportions of patients in a vegetative state
and all patients with severe disability were also increased. Patients
with severe disability include those with lower severe (dependent on
others and cannot be left alone for more than 8 h) and upper severe
disability (can be left alone in the home for more than 8 h, but are not
independent outside the home and cannot shop).1,15
The 12-month outcomes from the DECRA trial are presented
here and are considered in comparison with those of RESCUEicp.
Translation into clinical practice requires careful examination of
both randomized trials.
Methods
The design, patient inclusion and exclusion criteria, procedures,
assessments, outcome measures, study oversight, and statistical
analysis of the DECRA trial have been previously described.12 The
surgical procedure was a modification of the Kjellberg method,16
which had tested favorably in a cohort study.17 The only surgical
modification entailed not dividing the sagittal sinus and falx, to
minimize complications, decrease anterior herniation of the frontal
lobes, and increase generalizability.18 Randomization occurred
after ICU admission, when ICP had increased sufficiently to satisfy
the enrollment criteria.12 Patients in the intensive medical control
group could receive barbiturate infusions to control ICP, but not
hypothermia. Baseline variables were well matched except for
pupil reactivity at hospital admission, and outcomes at 6 months
favored the intensive medical control group.
Functional outcome assessments were conducted by trained
assessors, blind to treatment group, using standardized question-
naires.15,19 Functional outcome assessments at 12 months after
injury, and among survivors at 6 and 12 months, were pre-
planned14 and measured by the score on the GOS-E, which is
scored from 1 (dead) to 8 (pre-injury function).20 Among survivors,
favorable outcomes were calculated as the ratio of GOS-E scores 5–
8 over 2–8, and good outcomes as GOS-E scores of 7–8 over 2–8.
Functional (GOS-E) outcomes were dichotomized as unfavor-
able (1–4 vs. 5–8), and analyzed using logistic regression. Out-
comes (GOS-E) on a 1–8 scale were analyzed using ordinal logistic
regression. Among survivors at 6 and 12 months after injury, GOS-
E outcomes were analyzed using logistic regression for favorable
outcomes, and for three additional dichotomies: vegetative (2 vs. 3–
8), poor outcomes (2–4 vs. 5–8), and good outcomes (7–8 vs. 2–6).
The last three were post hoc exploratory analyses.
Multiple covariates influence patient outcomes after TBI, but
there were too many to reliably adjust for in a medium-sized ran-
domized trial. We therefore adjusted using a single summary
measure of brain injury severity—the estimated probability of
Table 1. Baseline Characteristics of 155 Patients
in Decompressive Craniectomy (DC), and Standard
Intensive Medical Care (Standard Care) Groups
DC,
n = 73
Standard
Care,
n= 82 P-value
Age (years) 0.89
Median 23.7 24.6
Interquartile range 19.4-29.6 18.5-34.9
GCS motor 0.49
Median 3 3
Interquartile range 1-4 1-5
Marshall class 0.39
Diffuse injury II; n (%) 17 (23) 27 (33)
Diffuse injury III/IV; n (%) 53 (73) 53 (65)
Non-evacuated mass lesion 3 (4) 2 (2)
Reactivity of pupils—
randomization
0.60
One or both pupils; n (%) 61/73 (84) 71/82 (87)
Reactivity of pupils—admission 0.04
One or both pupils; n (%) 52/71 (73) 70/80 (88)
Hypoxemia 18 (25) 24 (29) 0.55
Hypotension 24 (33) 25 (30) 0.93
Probability of unfavorable
outcome using IMPACT21;
core % (SD)
42 (19) 42 (20) 0.81
Probability of unfavorable
outcome using IMPACT21;
extended % (SD) n = 148a
48 (22) 45 (22) 0.40
aSeven patients had missing variables for hypoxic and/or hypotensive
insults, required for IMPACT extended calculation.
GSC, Glasgow Coma Scale; SD, standard deviation.
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unfavorable outcome from the International Mission for Prognosis
and Analysis of Clinical Trials in TBI (IMPACT) core and ex-
tended algorithms.21 IMPACT outcome probabilities are derived
from large databases of patients with TBI, and include the relevant
covariates, that is, IMPACT core including age, Glasgow Coma
Scale (GCS) motor score, pupil reactivity; and IMPACT extended,
which also includes CT score, and hypoxic and hypotensive events.
The single IMPACT outcome probability value provides an overall
summary measure of TBI severity in both study groups (Table 1).
TBI severity can be difficult to assess when covariates are many, or
move in different directions. We used pupil reactivity at trial ran-
domization for these calculations, as this measure best reflects a
patient’s post-resuscitation neurology, more so than does pupil re-
activity at hospital admission, which we had used previously.12 Pa-
tient outcomes at 6 and 12 months post-injury were adjusted for the
probability of an unfavorable outcome by using the IMPACT value
as a continuous variable in the linear predictor of the appropriate
regression model. The IMPACT extended model provided maximal
adjustment but included missing data on hypoxia/hypertension for
seven patients who were hence excluded; the IMPACT core proba-
bility of unfavorable outcome could be calculated for all 155 pa-
tients, and was the primary adjustment covariate.
An unplanned exploratory as-treated analysis was also conducted
of all patients who received a decompressive craniectomy at any time
after randomization compared with all those who did not, regardless
of randomized group. We wished to explore the effect on our results
of the 18% of standard care patients who had received a late cra-
niectomy as permitted in the protocol as a life-saving intervention.
Owing to likely imbalance in severity, all these analyses were ad-
justed for the IMPACT core probability of unfavorable outcome.
Results
One hundred fifty-five patients were randomized, 73 to decom-
pressive craniectomy and 82 to standard care. Baseline character-
istics including pupil reactivity at randomization in ICU (84% and
87%) and IMPACT probability of a poor outcome (42% and 42%
using IMPACT core) were similar between groups (Table 1).12
Pupil reactivity at randomization was considered the optimal in-
dicator of post-resuscitation neurological activity.
After randomization, more standard care patients (77%) than
patients with craniectomy (32%) required barbiturates to manage
ICP ( p< 0.001), more required high total doses of barbiturates
(>30 g; 17%) compared with zero in patients with craniectomy.22
Further, the post-randomization median total dose of barbiturates
received by standard care patients (6.5 g, interquartile range [IQR]
0.50–20) was substantially greater than that received by patients
with craniectomy (0.00 g, IQR 0.00–1.03, p < 0.001).
As previously reported,12 short-term outcomes in the ICU in the
craniectomy group compared with the standard care group had
improved, including lower ICP, fewer interventions to control ICP,
and fewer days receiving mechanical ventilation in the ICU.
Standard care patients also often received high-dose barbiturate
infusions to control their ICP.
Twelve months after injury, no patients were lost to follow-up, and
all 155 patients (100%) had neurological function assessed (Fig. 1).
For a patient participation diagram to 12 months see the supple-
mentary appendix published previously.22 Unlike the previously re-
ported 6-month results, at 12 months, the functional assessment on the
GOS-E (OR for a worse functional outcome in the craniectomy group
1.68; 95% CI: 0.96-2.93; p= 0.07), although concerning, was no
longer significantly worse in the craniectomy group. Unfavorable
outcomes occurred in 43 patients (59%) in the craniectomy group and
in 39 patients (48%) in standard care (OR 1.58; 95% CI: 0.84-2.99;
p= 0.16) (Table 2). After adjustment for IMPACT core score the
results were similar (Table 3). In summary, 12 months after TBI some
patients who had unfavorable outcomes at 6 months had improved
sufficiently that the trend to worse functional outcomes after cra-
niectomy was no longer significant.
Twelve months after injury, a total of 15 patients (21%) in the
craniectomy group and 16 (19%) in the standard care group had
died. Among the survivors at 12 months, vegetative outcomes
occurred in 14% of the craniectomy group, compared with 3% of
the standard care group (OR 5.12; 95% CI: 1.04-25.2; p = 0.04)
(Table 3). The proportion of severe disability (dependent) survi-
vors at 12 months was 48% in the craniectomy group, compared
with 35% in the standard care group (OR 1.74; 95% CI: 0.85-3.59;
FIG. 1. Functional outcomes in 155 patients at 6 and 12 months measured by the Glasgow Outcome Scale-Extended (GOS-E) in
decompressive craniectomy (DC), and standard intensive medical care (Standard Care) groups.
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p = 0.13). Good neurological outcomes in survivors at 12 months
were less common in the craniectomy group (10%) than the
standard care group (26%) (OR 0.33; 95% CI: 0.12-0.91; p = 0.03)
(Table 3).
At 6 months after injury the previously reported unadjusted risk of
an unfavorable outcome (OR 2.21; 95% CI: 1.14-4.26; p= 0.02)
(DECRA 2011),12 and the adjusted risk of an unfavorable outcome
using IMPACT core probability of unfavorable outcome (OR 2.40;
95% CI: 1.18-4.91; p= 0.02) were both greater in the craniectomy
group compared with standard care group. Among survivors at 6
months, in the craniectomy group the proportion of patients in a
vegetative state was greater (OR 5.85; 95% CI: 1.21-28.3; p= 0.03),
and the proportion of patients who were dependent was also greater
(63% vs. 40%; OR 2.49; 95% CI: 1.21-5.11; p= 0.01).
In an unplanned as-treated analysis, adjusted for IMPACT core,
of all patients who received a decompressive craniectomy at any
time compared with all those who did not, regardless of their ran-
domized group, at 6 months unfavorable functional outcomes were
increased in the craniectomy group (OR 2.04; 95% CI: 1.10-4.20;
p= 0.05), whereas at 12 months the same trend was evident
(OR 1.95; 95% CI: 0.97-3.99; p = 0.06).
Discussion
Some adults with severe diffuse TBI have increased ICP, which
is refractory to usual therapies, leading clinicians to consider bar-
biturate infusions, hypothermia, or decompressive craniectomy
surgery. In the DECRA trial of decompressive craniectomy com-
pared with standard intensive medical therapies, despite immediate
benefits in ICU, at 6 months the patients’ functional outcomes were
worse. They remained worse at 6 months after using IMPACT core
to adjust for baseline balance.
The DECRA trial outcomes at 12 months were important to
guide translation to patient care. At 12 months the rates of death,
and severe and moderate disability in both study groups were
similar. Decompressive craniectomy did not improve (and did not
significantly worsen) patients’ overall functional independence.
However, among survivors at 12 months more patients with cra-
niectomy were vegetative and fewer had good neurological out-
comes. Our unplanned as-treated analysis confirmed that patient
crossover for ethical reasons did not influence the trial findings at
either time-point. These results will assist informed-consent dis-
cussions with families, prior to decompressive craniectomy surgery.
There were more independent patient outcomes at 12 compared
with 6 months after injury in both study groups, and the reasons are
likely multi-factorial. First, many patients with TBI improve their
functional status over at least 12 months. Second, some compli-
cations including hydrocephalus requiring a shunt related to the
surgeries were more common in craniectomy patients, and may
have improved gradually over 12 months. Another may be the
potential adverse effects of an injured brain not having the pro-
tection of overlying skull for weeks or months after injury. Other
complications, relating to the unavoidable transport of critically ill
patients with brain swelling or post-operative hemorrhagic com-
plications and neurophysiological instability to and from operating
theaters, may also have slowly improved over time. Cerebral white
Table 2. Extended Glasgow Outcome Scale
at 12 Months in Decompressive Craniectomy (DC)
and Standard Intensive Medical Care
(Standard Care) Groups
GOS-E Score: n [%]
DC,
n = 73
Standard
Care, n= 82
1, Dead 15 [21] 16 [19]
2, Vegetative 8 [11] 2 [3]
3, Low severe disability 14 [19] 13 [16]
4, Upper severe disability 6 [8] 8 [10]
5, Low moderate disability 10 [14] 10 [12]
6, Upper moderate disability 14 [19] 16 [19]
7, Low good recovery 4 [5] 13 [16]
8, Upper good recovery 2 [3] 4 [5]
Unfavorable score (GOS-E <5): n [%] 43 [59] 39 [48]
GOS-E, Glasgow Outcome Scale-Extended.
Table 3. Dichotomized Functional Outcomes in All Patients and in Survivors at 6 and 12 Months after Injury
with and without Adjustment for the IMPACT Core Probability of a Favorable Outcome
Functional outcome using Glasgow
Outcome Scale-Extended (GOS-E)
DC vs. Standard Care
Unadjusted Adjusted
% with dichotomous outcome OR 95% CI P-value OR 95% CI P-value
6 months after injury
Unfavorable, all patients (1-4/1-8) 70% vs. 51%
n= 155
2.21 1.14-4.28 0.02 2.40 1.18-4.91 0.02
Vegetative survivors (2/2-8) 15% vs. 3%
n= 126
5.85 1.21-28.3 0.03 5.96 1.15-30.9 0.03
Severe disability survivors (2-4/2-8) 63% vs. 40%
n= 126
2.49 1.21-5.11 0.01 2.52 1.18-5.37 0.02
Good outcome survivors (7-8/2-8) 5% vs. 10%
n= 126
0.46 0.11-1.86 0.28 0.48 0.12 to-1.97 0.31
12 months after injury
Unfavorable, all patients (1-4/1-8) 59% vs. 48%
n= 155
1.58 0.84-2.99 0.16 1.65 0.83-3.28 0.15
Vegetative survivors (2/2-8) 14% vs. 3%
n= 124
5.12 1.04-25.2 0.04 5.16 0.95-27.9 0.06
Severe disability survivors (2-4/2-8) 48% vs. 35%
n= 124
1.74 0.85-3.59 0.13 1.70 0.80-3.62 0.17
Good outcome survivors (7-8/2-8) 10% vs. 26%
n= 124
0.33 0.12-0.91 0.03 0.34 0.12-0.94 0.04
CI, confidence interval; OR, odds ratio.
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matter stretch and injury to herniating frontal lobes at the edge of a
craniectomy are further potential surgical complications that may
also have improved over time.
One implication from these 12-month outcome results from the
DECRA trial is that therapies for ICP control should be assessed
through a risk-benefit lens. In the standard care patients in DECRA,
less rigorous ICP control most often using intravenous barbiturates
provided similar overall outcomes, but with fewer vegetative and more
good outcome survivors than decompressive surgery. The interna-
tional consensus ICP treatment thresholds for clinical interventions in
patients with neurotrauma may require further reconsideration.6,13,23
Further, because the standard care patients in the DECRA trial re-
ceived increased medical therapies usually including barbiturate in-
fusions, in patients with diffuse injury with early intracranial
hypertension risk-benefit considerations favor these medical therapies
rather than early decompressive craniectomy surgery. International
consensus guidelines concerning decompressive craniectomy in the
management of patients with TBI were recently published.24
Future potential modifications of the craniectomy surgery
technique are unlikely to change our results: hinged cranioto-
my,25–27 unilateral craniectomy, or even not opening the dura at all
are strategies that limit brain herniation, but were not tested in the
DECRA trial. DECRA excluded patients with intracranial hema-
tomas (mass lesions) as these patients often require craniectomy to
evacuate hemorrhage, and it also did not include patients with
penetrating gunshot or blast craniocerebral injury.
In comparison with DECRA, the randomized RESCUEicp de-
compressive craniectomy trial enrolled older patients with severe
TBI with a higher ICP threshold, included both diffuse injury and
mass lesions etiologies up to 10 days after injury, and found in-
creased survival. Favorable outcomes were defined differently in the
two trials. In DECRA, patients with favorable outcomes defined in
the standard way when the trial was conducted (patients living in-
dependently with GOS-E scores of 5–8) were decreased after cra-
niectomy at 6 months, and by 12 months this trend was no longer
significant. In RESCUEicp after examination of overall patient se-
verity, favorable outcomes were defined as GOS-E scores 4–8 (in-
cluding patients who were independent in the home for more than
8 h, but not outside the home). These were unchanged at 6 months,
and increased at 12 months. However, in these older, higher severity
patients in RESCUEicp, almost all the increased survivors after de-
compressive craniectomy at 12 months were vegetative or had either
lower or upper severe disability. In RESCUEicp there were increased
favorable outcomes at 12 months after craniectomy, primarily be-
cause the upper-severe disability outcomes were increased, and were
grouped as favorable. This is a valid approach, but it is a matter
of opinion as to whether independent living in the home, includ-
ing the inability to function independently outside or do the shop-
ping after severe TBI, is an optimal target for patients and families.
RESCUEicp did not increase fully independent outcomes.
Taken together, the DECRA and RESCUEicp trial results at 6
and 12 months inform clinicians that decompressive craniectomy
surgery does not improve survival when used prior to hypothermia
and/or barbiturates, but does improve survival when used after
these therapies in older patients with higher baseline mortality at
higher ICP thresholds. Both trials found that decompressive cra-
niectomy did not improve functional outcomes at 12 months when
independent functional outcomes were defined as scores 5–8 on the
GOS-E. Both trials also found that decompressive craniectomy
increased vegetative outcomes in survivors at 12 months.
Whether an increase in older patients surviving with severe
disability is a desirable outcome after severe TBI and whether it is
accurate to classify such an outcome as ‘‘favorable’’ in a ran-
domized trial is a matter for families and clinicians, and undoubt-
edly for ongoing debate. However, independence both inside and
outside the home (GOS-E scores 5–8) has defined ‘‘favorable
outcomes’’ for interventional randomized trials in TBI for decades
prior to RESCUEicp.
Strengths of the DECRA trial include prospective multi-center
design, size, randomization with concealed allocation, use of early
ventricular drainage as a pre-randomization therapy, blinded out-
come assessments, and the complete (100%) follow-up rate. In-
clusion of patients solely with diffuse TBI enabled clearer
conclusions about a more uniform pattern of brain injury. Strengths
of the outcome analysis at 12 months include the 100% follow-up
rate and the verification of baseline balance for patient severity
using IMPACT21 core as the adjustment covariate.
In this article, we resolved questions about pupil reactivity being
unbalanced compared with other baseline variables28 by utilizing
the post-resuscitation, last pre-randomization values. Overall
baseline severity was then quantified using the single IMPACT
probability of unfavorable outcome, and was found to be balanced.
Including patients solely with diffuse TBI may also be consid-
ered a limitation. By comparison, RESCUEicp enrolled patients
with both diffuse and mass lesion injury, but both trials found
similar increases in vegetative outcomes after surgery. RESCUEicp
did not separately report the outcomes of the two main injury types.
Other limitations may be that DECRA did not test salvage therapy
for extreme or late intractable ICP elevations, nor the effect of
withholding craniectomy surgery until ICP had reached higher
thresholds, whereas RESCUEicp randomized patients at a higher
ICP threshold of 25 mm Hg. A substantial number of standard care
patients in both DECRA (18%) and RESCUEicp (37.2%) received
a delayed decompressive craniectomy, by clinician direction.
However, the exploratory as-treated analysis of DECRA supported
the primary results. Finally, most patients in DECRA were from
high-income countries, and the results are not generalizable to
conditions in low-income countries with more limited facilities.24
Both trials used primary intention-to-treat analyses, because
alternative per-protocol analyses may be complicated by inevitable
baseline severity imbalances.
Twelve months after diffuse severe TBI, in patients who had
intracranial hypertension refractory to optimized first- and second-
tier therapies in their first 72 h, early decompressive craniectomy
compared with standard intensive medical care did not improve
survival or neurological outcomes. Exploratory analyses found that
early decompressive craniectomy increased vegetative survivors
and decreased survivors with good outcomes compared with
standard intensive medical therapies.
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